Related projects
Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
Adoptive cell therapy using transferred tumour infiltrating lymphocytes (TILs) is limited by the physical barrier created by a restrictive tumour microenvironment (TME) and by T-cell inactivation within the TME. Thus, minimizing the immunosuppressive effects of the TME and overcoming T-cell inactivation is crucial. AVID200 is a potent TGF-beta inhibitor designed by Forbius that selectively neutralizes TGF-beta1 & -beta3 with picomolar potency that reverses immunosupression, fibrosis & renders tumors sensitive to checkpoint blockade. In preclinical models, AVID200 was shown to effectively promote infiltration of TILs, activate cytolytic T cells and increase the responsiveness of immune checkpoint (ICP) inhibitors such as anti-PD-(L)1. ICP blockers (CTLA-4, PD-1, LAG3, TIM3, BTLA and others) have been shown to help restore anti-tumour immunity to a certain extent either alone or in combination therapies. Most of these ICP signal through SHP-1/-2 phosphatases, which have important inhibitory roles in T-cell activation. Accordingly, blocking SHP-1/SHP-2 within T-cells may help overcome their inactivation by targeting different ICP pathways simultaneously.
Réjean Lapointe
Cristina Chauvet
Formation Biologics
Medicine
Life sciences
Université de Montréal
Elevate
Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
Find the perfect opportunity to put your academic skills and knowledge into practice!
Find ProjectsThe strong support from governments across Canada, international partners, universities, colleges, companies, and community organizations has enabled Mitacs to focus on the core idea that talent and partnerships power innovation — and innovation creates a better future.